Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Q1 2026 results (May 7, 2026): cash, cash equivalents and short-term investments of $123.0M as of March 31, 2026 (vs $145.7M at 12/31/25); runway into…
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload — covering up to five new internally developed ADC…
Whitehawk Therapeutics announced a new option agreement with Hangzhou DAC providing access to CPT113 linker-payload technology for up to five additional…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Whitehawk Therapeutics entered a new option agreement with Hangzhou DAC for access to the CPT113 linker-payload technology for use in up to five additional ADC programs. Whitehawk will select targets and source antibodies while retaining global rights and full program control. Builds on Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation platform.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. / Hangzhou DAC Biotech Co., Ltd. (this deal) | 2026 | — | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2026 deals · Oncology deals